This company listing is no longer active
このページの翻訳は実験的なもので、現在開発中です。お待ちしております
Clover Biopharmaceuticals 将来の成長
Future 基準チェック /26
We currently don't have sufficient analyst coverage to forecast growth and revenue for Clover Biopharmaceuticals.
主要情報
n/a
収益成長率
190.4%
EPS成長率
Biotechs 収益成長 | 39.9% |
収益成長率 | 47.9% |
将来の株主資本利益率 | n/a |
アナリストカバレッジ | Low |
最終更新日 | 27 Jul 2023 |
今後の成長に関する最新情報
更新なし
Recent updates
業績と収益の成長予測
日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
---|---|---|---|---|---|
12/31/2025 | 2,341 | N/A | N/A | N/A | 1 |
12/31/2024 | 3,071 | N/A | N/A | N/A | 2 |
12/31/2023 | 2,571 | N/A | N/A | N/A | 2 |
6/30/2023 | 0 | -665 | N/A | N/A | N/A |
3/31/2023 | 0 | -1,559 | N/A | N/A | N/A |
12/31/2022 | N/A | -2,452 | -1,796 | -1,691 | N/A |
9/30/2022 | N/A | -4,145 | -1,461 | -1,356 | N/A |
6/30/2022 | N/A | -5,838 | -1,125 | -1,021 | N/A |
3/31/2022 | N/A | -5,927 | -1,062 | -969 | N/A |
12/31/2021 | N/A | -6,016 | -998 | -918 | N/A |
12/31/2020 | N/A | -913 | 363 | 477 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: Insufficient data to determine if 2197's forecast earnings growth is above the savings rate (1.9%).
収益対市場: Insufficient data to determine if 2197's earnings are forecast to grow faster than the Hong Kong market
高成長収益: Insufficient data to determine if 2197's earnings are expected to grow significantly over the next 3 years.
収益対市場: 2197's revenue (47.9% per year) is forecast to grow faster than the Hong Kong market (8.7% per year).
高い収益成長: 2197's revenue (47.9% per year) is forecast to grow faster than 20% per year.
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: Insufficient data to determine if 2197's Return on Equity is forecast to be high in 3 years time